BeOne to get $885M upfront in royalty deal over Amgen’s Imdelltra

BeOne Medicines is the latest biopharma to take advantage of the burgeoning royalty financing market. The drugmaker, recently renamed from BeiGene, will get $885 million upfront from Royalty Pharma, one of ...